Jacobs Levy Equity Management’s Solid Biosciences SLDB Stock Holding History

Jacobs Levy Equity Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,278	Closed	-$153K	–	1062
2021 Q3	$153K	Sell	4,278 -6,353	-60%	-$270K	﹤0.01%	1002
2021 Q2	$584K	Hold	10,631	–	–	﹤0.01%	836
2021 Q1	$882K	Sell	10,631 -10,198	-49%	-$1.13M	0.01%	765
2020 Q4	$2.37M	Buy	20,829 +9,265	+80%	+$586K	0.02%	542
2020 Q3	$352K	Buy	11,564 +4,325	+60%	+$166K	﹤0.01%	866
2020 Q2	$318K	Buy	7,239 +5,238	+262%	+$217K	﹤0.01%	875
2020 Q1	$72K	Buy	+2,001	New	+$99K	﹤0.01%	967

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's SLDB Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Solid Biosciences (SLDB) in Q4 2021, closing a stake of 4,278 shares — an estimated $153K sold.

Jacobs Levy Equity Management first reported a position in SLDB in Q1 2020 and held it in 7 quarters. The position peaked at $2.37M in Q4 2020. 82 funds tracked by Wall St. Rank hold SLDB as of Q4 2021.

Jacobs Levy Equity Management reported no remaining Solid Biosciences position as of Q4 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 4,278 Solid Biosciences shares in Q4 2021, an estimated $153K.
Jacobs Levy Equity Management first reported a position in Solid Biosciences in Q1 2020 and held it in 7 quarters.
Jacobs Levy Equity Management's Solid Biosciences position peaked at $2.37M in Q4 2020.
82 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.